Overview: Prolactin Immunohistochemistry TestIntroduction: The Prolactin Immunohistochemistry Test detects prolactin protein to diagnose pituitary tumors, causing hormonal imbalances or fatigue. Aligned with 2023 Endocrine Society guidelines, it uses immunohistochemistry for high specificity, supporting endocrine screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected pituitary tumors, such as prolactinomas.
Other Names: Prolactin IHC Assay, Pituitary Tumor IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: Prolactin testing began in the 1970s with pituitary research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision for pituitary adenomas.
Purpose: Detects prolactin to diagnose pituitary tumors, guides treatment, and evaluates patients with hormonal imbalances or fatigue.
Test Parameters: 1. Prolactin Protein
Pretest Condition: No fasting required. Collect tissue via pituitary biopsy or surgery. Report history of hormonal imbalances, fatigue, or galactorrhea.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document hormonal imbalances, fatigue, galactorrhea, infertility, or family history of pituitary disorders. Include current medications, especially dopamine agonists.
Consent: Written consent required, detailing the tests purpose, pituitary tumor implications, and risks of biopsy or surgery.
Procedural Considerations: Uses immunohistochemistry to detect prolactin in pituitary tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for prolactinoma diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive prolactin staining confirms prolactin-secreting pituitary tumors, guiding medical therapy (e.g., cabergoline) or surgery. Negative staining may require further endocrine testing.
Specialist Consultation: Consult an endocrinologist or neurosurgeon for result interpretation and treatment planning.
Additional Supporting Tests: Serum prolactin levels, pituitary MRI, or FSH IHC to confirm pituitary tumor diagnosis.
Test Limitations: Not specific to prolactinomas; other pituitary tumors may express prolactin. Clinical correlation is needed.
References: Endocrine Society Pituitary Guidelines, 2023; Journal of Clinical Endocrinology, Melmed S, 2022.
